SCHEMBL1607572

SCHEMBL1607572

Cc1cc(-c2nc(-c3cnc4[nH]ccc4c3)no2)cnc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.47
▸ CDK8 P49336 6/20 0.44
▸ AXL P30530 1/20 0.44
▸ PIK3CA P42336 4/20 0.43
▸ PIK3CD O00329 2/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ RIPK1 Q13546 3/20 0.42
▸ CDK7 P50613 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ DCLK1 O15075 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ PAK4 O96013 1/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ INSR P06213 1/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ FES P07332 1/20 0.42
▸ ROS1 P08922 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608396 0.81 APP (0.46) APPCDK8AXLPIK3CAPIK3CD
SCHEMBL1608526 0.79 APP (0.51) APPCDK8AXLPIK3CAPIK3CD
SCHEMBL1250873 0.76 NPC1 (0.50) NPC1RAB9AS1PR1S1PR3
SCHEMBL1422718 0.76 CHRNB2 (0.61) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL1607465 0.75 RIPK1 (0.50) APPCDK8AXLPIK3CAPIK3CD
SCHEMBL1250800 0.74 NPC1 (0.62) CDK8PIK3CDPIK3CBNPC1RAB9A
SCHEMBL1249937 0.74 MAPT (0.60) NPC1RAB9AS1PR1
SCHEMBL19745698 0.74 HDAC6 (0.56) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL1608528 0.73 NPC1 (0.49) NPC1RAB9AS1PR1
SCHEMBL1608446 0.72 RIPK1 (0.55) APPCDK8AXLPIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 APP 1/4885CDK8 4347/4885AXL 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback